RWA Wealth Partners’s Seres Therapeutics MCRB Stock Holding History

RWA Wealth Partners’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50	Closed	-$9K	–	516
2018 Q2	$9K	Buy	+50	New	+$8.17K	﹤0.01%	626

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RWA Wealth Partners's MCRB Position: Q3 2018 in Review

RWA Wealth Partners sold out of Seres Therapeutics (MCRB) in Q3 2018, closing a stake of 50 shares — an estimated $9K sold.

RWA Wealth Partners first reported a position in MCRB in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 72 funds tracked by Wall St. Rank hold MCRB as of Q3 2018.

RWA Wealth Partners reported no remaining Seres Therapeutics position as of Q3 2018 after selling out during the quarter.
RWA Wealth Partners sold 50 Seres Therapeutics shares in Q3 2018, an estimated $9K.
RWA Wealth Partners first reported a position in Seres Therapeutics in Q2 2018 and held it in 1 quarter.
RWA Wealth Partners's Seres Therapeutics position peaked at $9K in Q2 2018.
72 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2018.

Based on RWA Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.